Table 2.1 Top Ten M&A Deals in all Industries Worldwide, 2000-2009
Table 2.2 The Biggest Pharma M&A Deals of All Time ($bn)
Table 2.3 The Biggest Pharma M&A Deals ($bn), 2000-2009
Table 2.4 The 20 Biggest Pharma Companies Sales ($bn), Global Market Share (%), Historical M&A Activity, 2009
Table 2.5 M&A Activity: Number of Deals and Overall Deal Value ($bn), 2000-2009
Table 2.6 The Top 10 Drugs: Revenues ($bn) and Forecast Patent Expiry Date, 2009
Table 2.7 Some Pharma Industry Strategies for Minimising Revenue Loss, 2010
Table 2.8 The 15 Largest Pharma Partnership Deals ($bn), 2005-2009
Table 3.1 Pharma M&A deals over $0.5bn, 2009 and (up to Q2) 2010
Table 3.2 Pharma Industry Exposure to the Patent Cliff by 2012, Revenues ($bn), Proportion of Total Revenues ($bn)
Table 3.3 Pfizer's Top Products, 2009
Table 3.4 Pfizer Products Approaching Patent Expiry, 2010
Table 3.5 Pfizer's Pipeline, Phase III and Later, 2010
Table 3.6 Pfizer's Revenues ($bn), Growth (%), CAGR (%), 2005-2010
Table 3.7 Pfizer's Revenues ($bn), Growth (%), CAGR (%), 2010-2020
Table 3.8 Roche's Bestselling Products, Revenue ($bn), 2009
Table 3.9 Roche's Pipeline, Phase III and Later, 2010
Table 3.10 Roche's Revenues ($bn), Growth (%), CAGR (%), 2010-2020
Table 3.11 Merck & Co’s Pipeline, Phase III and Beyond, 2010
Table 3.12 Merck & Co’s Bestselling Products, Revenue ($bn), 2009
Table 3.13 Merck & Co’s Products Approaching Patent Expiry, 2010
Table 3.14 Merck & Co’s Revenues ($bn), Growth (%), CAGR (%), 2010-2020
Table 3.15 Merck KGaA's Pipeline, Phase III and Beyond, 2010
Table 3.16 Merck KGaA's Revenues ($bn), Growth (%), CAGR (%), 2010-2020
Table 3.17 Abbott's Pipeline, Phase III and Beyond, 2010
Table 3.18 Abbott's Revenues ($bn), Growth (%), CAGR (%), 2010-2020
Table 3.19 The Top 10 Generic Market M&A Deals 2000-2010 (up to Q2)
Table 3.20 The Top Generic Companies: Revenues ($bn), Annual Growth (%), 2009
Table 3.21 Teva's Revenues ($bn), Growth (%), CAGR (%), 2010-2020
Table 3.22 Important M&A and Alliance Activity in the Generics Sector, 2000-2010
Table 3.23 Japan-US M&A deals, 2009-2010 (up to Q2)
Table 3.24 Dermatology Products of GSK and Stiefel Laboratories, 2010
Table 4.1 Biotechnology M&A Activity: Number of Deals and Overall Deal Value ($bn), 2000-2009
Table 4.2 The Largest Biotech Companies by Revenues ($bn), 2009
Table 4.3 Biotech M&A Target Companies and Possible Acquirers, 2010
Table 4.4 Biogen Idec: Products and Pipeline, 2010
Table 4.5 Genzyme: Products and Pipeline, 2010
Table 4.6 Celgene: Products and Pipeline, 2010
Table 4.7 Vertex: Products and Pipeline, 2010
Table 4.8 Human Genome Sciences: Pipeline, 2010
Table 4.9 Crucell: Products and Pipeline, 2010
Table 4.10 Intercell: Products and Pipeline, 2010
Table 4.11 Seattle Genetics: Pipeline, 2010
Table 4.12 Alexion: Products, 2010
Table 4.13 Immunogen: Pipeline, 2010
Table 4.14 United Therapeutics: Products and Pipeline, 2010
Table 4.15 Onyx Pharmaceuticals: Products, 2010
Table 4.16 Auxilium Pharmaceuticals: Products, 2010
Table 4.17 Allos Therapeutics: Products, 2010
Table 4.18 Amylin Pharmaceuticals: Products and Pipeline, 2010
Table 4.19 BioMarin Pharmaceutical: Products and Pipeline, 2010
Table 4.20 Rigel Pharmaceuticals: Pipeline, 2010
Table 5.1 SWOT Analysis for Pharma Industry M&A, 2010-2020
Figure 2.1 Companies' Shares of the Global Pharma Market (%), 2009
Figure 2.2 Company Revenue Growth (%) for the Top 20 Pharma Companies, 2009
Figure 2.3 Number of M&A Deals, 2000-2009
Figure 2.4 Value of M&A Deals ($bn), 2000-2009
Figure 2.5 Number and Value of M&A Deals ($bn), 2000-2009
Figure 2.6 NCEs Receiving FDA Approval, 2002-2009
Figure 2.7 Revenue Lost to Patent Expiry 2009 ($m) and Predicted Revenue Loss After Patent Expiry ($m), 2010-2014
Figure 3.1 Pharma Industry Exposure to the Patent Cliff by 2012, Revenues ($bn)
Figure 3.2 Pfizer’s Revenues ($bn), 2005-2010
Figure 3.3 Pfizer’s Revenues ($bn), 2010-2020
Figure 3.4 Pfizer’s Revenues ($bn), with and Without the Effects of the Wyeth Merger, 2010-2020
Figure 3.5 Roche’s Revenues ($bn), 2010-2020
Figure 3.6 Merck & Co's Revenues ($bn), 2010-2020
Figure 3.7 Merck KGaA’s Revenues ($bn), 2010-2020
Figure 3.8 Abbott’s Revenues ($bn), 2010-2020
Figure 3.9 Teva’s Revenues ($bn), 2010-2020
Figure 4.1 Number of Biotechnology M&A Deals Compared to Traditional Pharmaceutical M&A Deals, 2000-2009
[Fade out list of tables / figures]
